Article Abstract

Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?

Authors: Paul Zarogoulidis, Vasilis Papadopoulos, Elena Maragouli, George Papatsibas, Haidong Huang

Abstract

Tyrosine kinase inhibitors (TKIs) is the best treatment choice for patients with epidermal growth factor receptor mutation (EGFR) (1).